021-51111890
购物车（0）
sales@molnova.cn
WYC209
CAS No. 2131803-90-0
WYC209 ( —— )
产品货号. M20092 CAS No. 2131803-90-0
WYC-209 抑制恶性鼠黑色素瘤肿瘤再生细胞的增殖（TRC，IC50：0.19 uM）。它的目标是视黄酸受体（RAR）。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ￥446 | 有现货 |
|
| 10MG | ￥721 | 有现货 |
|
| 25MG | ￥1531 | 有现货 |
|
| 50MG | ￥2406 | 有现货 |
|
| 100MG | ￥3945 | 有现货 |
|
| 200MG | 获取报价 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称WYC209
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述WYC-209 抑制恶性鼠黑色素瘤肿瘤再生细胞的增殖（TRC，IC50：0.19 uM）。它的目标是视黄酸受体（RAR）。
-
产品描述WYC-209 inhibits proliferation of malignant murine melanoma tumor-repopulating cells (TRCs IC50: 0.19 uM). It targets the retinoic acid receptor (RAR).
-
体外实验WYC-209 (10 μM; 24 hours) is able to inhibit and block growth of TRCs of human tumor cells in culture with a long-lasting effect. Apoptosis Analysis Cell Line:A2780, A549, MCF-7, MDA-MB-435s, A375 cells Concentration:10?μM Incubation Time:24 hours Result:TRCs failed to resume growth 5 days after the drug washout.
-
体内实验WYC-209 (0.022-0.22 mg/kg; i.v.; once every two days for 25 days) inhibits tumor metastasis in C57BL/6 mice bearing lung metastases. Animal Model:Female immune-competent C57BL/6 mice Dosage:0.022, 0.22?mg/kg Administration:Intravenous injection; once every two days for 25 days Result:Four out of eight mice formed lung metastases at dose of 0.022?mg?/kg, only one out of eight mice formed lung metastases at dose of 0.22?mg/kg.
-
同义词——
-
通路Metabolic Enzyme/Protease
-
靶点Retinoid Receptor
-
受体RAR
-
研究领域——
-
适应症——
化学信息
-
CAS Number2131803-90-0
-
分子量368.45
-
分子式C20H20N2O3S
-
纯度>98% (HPLC)
-
溶解度DMSO: 80 mg/mL (217.13 mM);Water: Insoluble
-
SMILESCCOC(=O)c1cnc(nc1)C#Cc1ccc2c(c1)C(C)(C)CCS2=O
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Chen J et al. Inhibition of cancer stem cell like cells by a synthetic retinoid. Nat Commun. 2018 Apr 11;9(1):1406.
